Navigation Links
New molecules discovered that block cancer cells from modifying cell DNA

Lake Tahoe, CA, October 11, 2007 Researchers have discovered new small molecules that may prevent prostate cancer cells from turning off normal genes in a process that transforms normal cells into cancer cells. This significant discovery in the field of epigenetics has immediate implications in the development of new diagnostic tests and cancer medications. The findings were presented today at the Prostate Cancer Foundations annual Scientific Retreat. Funding for the research was provided by the Prostate Cancer Foundation, as well as from the National Cancer Institute and the Avon Foundation.

Epigenetics refers to changes to genes other than changes to the DNA sequence itself, such as the addition of molecules to the DNA strand. While the development of cancer can arise from defective or mutated genes, it can also arise from these changes that can actually prevent a cell from acting as it should. Cancer cells exploit this process, putting some genes in cold storage or turned off by modifying the cell DNA in a process known as methylation.

Lead researcher William Nelson, M.D., Ph.D., Professor of Oncology and Urology at the Johns Hopkins Kimmel Cancer Center, explained the findings. One of the proteins in the cell that triggers this process is called a methyl-CpG binding protein, or MBD. We have discovered an antagonist of MBD2 that keeps this protein from binding to methylated genes. If the protein cant bind to the gene, then it cant keep the gene turned off and the gene is turned back on able to act in the way it is supposed to.

Nelson noted that the discovery is particularly exciting because of previous research that shows the importance of being able to alter the methylation process in DNA. When mice were developed without the gene that permits this process, they dont develop cancer. When the gene is removed from cancer cells, they turn on genes again in appropriate ways. The small molecules that weve discovered mimic this process, so they may be very exciting lead candidates for the next generation of drugs that may help restore gene function in prostate cancer, said Nelson.

This entire field of exploration has been tantalizing for a decade, said Nelson, but has only begun to deliver fruit in just the past couple of years. This mechanism of action permits us to look for much more targeted therapies for prostate cancer, and for other cancers as well, such as breast cancer.

The promise of this field is evident in the current pipeline of diagnostic and therapeutic products in development. There are diagnostic tests being tested that focus on detecting the methylated DNA, which would permit prostate cancer diagnosis at an earlier stage and in a more precise manner. There is also a first generation of FDA-approved medications that work to reverse the methylation process in cancer cells. They include azacitine (Vidaza) and decitabine (Dacogen), both for the treatment of myelodysplastic syndrome, diseases in which the production of blood cells by the bone marrow is disrupted. Vorinostat (Zolinza) also works to turn back on silenced genes, and is approved for use in cutaneous T cell lymphomas.

Dr. Nelson noted that the Prostate Cancer Foundation funding was essential for the research that resulted in this discovery. PCF supported our research at a time when it was a very new idea. Their investment permitted us to make critical discoveries that have not only put us along the pathway this field -- hopefully one day resulting in new drugs -- but that also allowed us to secure competitive research funding from the National Cancer Institute, explained Nelson.


Contact: Sharon Reis

Related biology news :

1. DNA Molecules Used To Assemble Nanoparticles
2. Inflammatory molecules released by pollen trigger allergies
3. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
4. Medical molecules designed to respond to visible light that can penetrate tissue
5. Touching Molecules With Your Bare Hands
6. DNA constraints control structure of attached macromolecules
7. Team Invents Device For Weighing Individual Molecules
8. Scientists discover that three molecules may be developed into new Alzheimers drugs
9. Physical and functional interaction of key cell growth molecules linked to cancer
10. Scientists discover new way to look at how molecules twist and turn on water
11. Scientists learn to predict protein-stabilizing ability of small molecules
Post Your Comments:
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... , ... The Academy of Model Aeronautics (AMA), led by its Executive Council, ... Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing has ... type of racing and several new model aviation pilots have joined the community because ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology: